13F filer · CIK 1457494
Delphi Management Partners VIII, L.L.C.
San Mateo, CA · filing since Q4 2019 · last filing Nov 15, 2021
Reported value
$138.5M
+$11.8M vs prior
Positions
4
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%
Biggest buys vs Q2 2021
No new or increased positions this quarter.
Biggest sells vs Q2 2021
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2021
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Tandem Diabetes, Inc.COMMON STOCK | 1,000,000 | $119.4M | 86.22% |
| 2 | Karyopharm Therapeutics, Inc.COMMON STOCK | 2,263,006 | $13.2M | 9.51% |
| 3 | Calithera Biosciences, Inc.COMMON STOCK | 2,426,702 | $5.3M | 3.82% |
| 4 | Mereo BioPharma Group PLCADS | 256,734 | $621.0K | 0.45% |